



# Methodological Note – 2020

---

Accompanying document for the public Transparency  
of Transfer of Value to Healthcare Professionals and  
HealthCare Organizations

**Takeda Farmacéutica España S.A.**

**Issue date : 20/May/2021**

# Methodological Note 2020

---

<b>1. General introduction .....</b>	<b>3</b>
<b>2. Scope of the disclosure .....</b>	<b>3</b>
2.1. Recipient scope.....	3
2.1.1. <i>Healthcare Professionals: definition and scope</i> .....	3
2.1.2. <i>Healthcare Organisations: definition and scope</i> .....	3
2.1.3. <i>Patient Organisations: definition and scope</i> .....	3
2.1.4. <i>Company owned by an HCP</i> .....	4
2.1.5. <i>Clearly identifiable recipient</i> .....	4
2.2. Medicinal scope.....	4
2.3. Takeda definitions of Transfer of values activities .....	4
2.3.1. <i>Donations and grants</i> .....	4
2.3.2. <i>Contribution to costs of event</i> .....	4
2.3.3. <i>Fees for service and consultancy</i> .....	5
2.3.4. <i>Research &amp; Development</i> .....	5
2.4. Transfer of value in cross border interactions.....	6
2.5. Transfer of value with Patient organization .....	6
<b>3. Privacy consent to the disclosure and aggregate amount.....</b>	<b>6</b>
<b>4. Working assumptions.....</b>	<b>7</b>
4.1. Transfer of Value date.....	7
4.2. Currency.....	7
4.3. Taxes .....	8
4.3.1 VAT.....	8
<b>5. Dispute Resolution management .....</b>	<b>8</b>

## 1. General introduction

Collaboration between industry and health professionals benefits patients. It is a relationship that has delivered numerous innovative medicines and changed the way many diseases impact on our lives. Industry and health professionals collaborate in a range of activities from clinical research, sharing best clinical practice and exchanging information on how new medicines fit in to the patient pathway. Bringing greater transparency to this, already well-regulated, vital relationship is about building strengthening the basis for collaboration in the future. Society has increasingly high expectations for transparency, none more so than in healthcare. Takeda, as a member of the European Federation of Pharmaceutical Industries Associations (“EFPIA”), want to ensure we meet those expectations going forward.

In January 2019, Takeda acquired Shire. According to EFPIA guidance, Shire will disclose its 2019 ToV in 2020 separately from Takeda. Starting with the 2020 disclosure period in 2021 as Takeda, it will be conducted as a single entity, unless local laws or regulations require otherwise.

This methodological note is intended to anyone who wants to better understand the working assumptions used to generate Takeda Spain disclosure report and how the disclosed activities are defined within Takeda.

## 2. Scope of the disclosure

Several internal interpretations were required in order to properly identify what is reportable Transfer of values (ToV) under current year EFPIA guidelines

([https://www.efpia.eu/media/554677/efpia\\_codes\\_a5\\_v3-2021\\_sm.pdf](https://www.efpia.eu/media/554677/efpia_codes_a5_v3-2021_sm.pdf)), and the Code of good practices for Pharmaceutical industry and Farmaindustria

(<https://www.codigofarmaindustria.org/servlet/sarfi/codigo/codigo.html>).

We have summarized below our interpretation and working assumptions which we consistently applied while gathering data, what covered recipients’ means for us and the covered activities and expenses that are in scope.

### 2.1. Recipient scope

#### 2.1.1. Healthcare Professionals (HCP): definition and scope

In the disclosure report, Takeda has taken into account the definition of HCPs as per the Spanish Code of good practices for Pharmaceutical industry and Farmaindustria with whom we may have transfer of values. The address of publication of the HCPs that are taken into account in the disclosure report is the primary practice address of the HCP.

#### 2.1.2. Healthcare Organisations (HCO): definition and scope

In the disclosure report, Takeda has taken into account the definition of HCOs as per the Spanish Code of good practices for Pharmaceutical industry and Farmaindustria For instance, here type of HCOs with whom we may have transfer of values: *Associations, Hospital Federation, Hospital department, Care education centre, Clinic, Dental Clinic, Dispensary, Institution, Faculty, University, Academy school, Foundation, Grouping of pharmacies, Health institution*. The address of publication of the HCOs - that are taken into account - is the public address of the HCO.

#### 2.1.3. Patient Organisations (PO): definition and scope

In the disclosure report, Takeda has taken into account the definition of Patient Organizations as per the Spanish Code of good practices for Pharmaceutical industry and Farmaindustria and in accordance with it, transfers of value are published.

#### 2.1.4. Company owned by an HCP

If the company (HCO) is owned by one or more than one HCP, the transfer of value is reported against the individual HCO.

#### 2.1.5. Clearly identifiable recipient

Takeda has put in place an internal process in order to ensure that transfer of values are allocated to the proper HCP or HCO, and to ensure that the disclosed information is accurate and complete (e.g. name, address, unique official ID whenever required, primary country of practice). In cases where the NIF / CIF is not available at the time of publication, it will be reflected as XXXXXX, and the information will be published as soon as it is available, in a new version of the transparency report, which will be duly published on its website.

### 2.2. Medicinal scope

The report only refers to prescription only medicine supplied by Takeda.

### 2.3 Activities scope

The activity definitions may vary amongst companies. Within Takeda, all our interactions with HealthCare Professionals are guided by TAKEDA internal Policies and Standard Operating Procedures that have been developed in alignment with local country laws and regulations and local industry requirements. We are providing you below with our Company definitions to ease our Disclosure report reading.

#### 2.3.1 Donations and grants to HCO

All the transfer of values regarding a donation or a grant between Takeda and a HCO are included in the scope of the disclosure. This transfer of values could be for instance:

- i. Donations (monetary and non-monetary)
- ii. Charitable contributions (if the organization is classified as HCO in the country)
- iii. Grants, as following:
  - o Medical educational grants (e.g. support of the education of HCPs): they could be monetary in nature (e.g. IISRs, defined as unsolicited, independent research whether the investigator or the institution (academic, private or governmental) serves as the sponsor and Takeda provides support in the form of study drug and /or funding), and non-monetary (i.e. benefits in kind such as. anatomical models)
  - o Non-Medical educational grants (e.g. support healthcare institutions in improving infrastructure)

#### 2.3.2 Contribution to costs of event

All the transfer of values regarding a contribution to costs of event between Takeda and a HCP (directly, or indirectly via a third party) or an HCO are included in the scope of the disclosure. These transfers of values could be for instance:

- i. A travel fee (*e.g. flight, train, taxi, car hire, tolls, mileage reimbursement, parking, visa or other official documents necessary for an HCP to secure travel arrangements, travel health insurance, etc.*)
- ii. An accommodation fee
- iii. A registration fee (*Fees paid for a HCP or a HCO, to allow HCPs to attend medical/educational events not organized by Takeda*)
- iv. A sponsorship agreement with an HCO or a third party appointed by an HCO to manage an event, for instance *Third Party scientific Conferences, Congresses or Exhibits; Sponsorships via Medical Societies; National Industry Organizations; Hospitals and Teaching Institutions; Scientific*

*Organizations; Regional, National, International and Global Conferences; Local Hospitals; Medical Centres.*

Whenever an HCP being sponsored to a third party meeting had to cancel his/her participation, this has not been included in our report, nor is any cancellation fees.

Examples of activities that could be covered under “Sponsorship agreements” in the Takeda disclosure report: *Rental of booth, advertisement space (electronic, paper, etc.), satellite symposia at a scientific congress, scientific courses provided by a HCO, opportunities to promote our products (including non-promotional), meeting sponsorships (e.g. organisation support)*

### 2.3.3 Fees for Service and Consultancy

All the transfer of values regarding a fee for services and consultancy between Takeda and a HCP or a HCO are included in the scope of the disclosure. These transfer of values concerns for instance a meeting or event (promotional or non-promotional) where the HCP or the HCP working for an HCO is a speaker, a trainer, an advisor, and could be:

- i. Fees (e.g. fee for services such as preparation time, rehearsal time, travel time and time required for the activity)
- ii. Related expenses to consultancy (e.g. travel cost accommodation fee.)

Examples of fees that could be covered under “Fee for Services & Consultancy (HCPs and HCOs)” in the Takeda disclosure report: *Speaker fees for Speaker Programs and Roundtables; Ad Hoc Consulting/Advising Arrangements; Faculty for Speaker Training Programs or training of Takeda employees or external parties; Faculty for Advisory Board Meetings; Study participant for Market Research (only if no double-blinded research); Medical writing; Data analysis; Development of educational materials; Market survey (only if not double-blinded survey); Consultancy (e.g. protocol advise, market access, reimbursement, high technology assessment)*

### 2.3.4 Research & Development

Transfer of values related to a Research and Development (R&D) activity are included in the scope of the disclosure. These transfers of values include transfer of values to HCPs or HCOs related to the planning or conduct of:

- i. Non-clinical studies intended for submission to regulatory authorities (as defined in OECD Principles on Good Laboratory Practice)
- ii. Clinical trials (as defined in European Directive 2001/20/EC)
  - a. Any clinical trial in humans using an unapproved medicinal product;
  - b. Any clinical trial in humans using an approved medicinal product where it will be used for an unapproved indication or otherwise it will be prescribed outside the terms of its marketing authorisation, or where patients are prospectively assigned to different treatments, or where the protocol requires diagnostic or monitoring procedures which would not have been performed if the patient was not in the trial;
  - c. Any other clinical trial in humans for which clinical trial approval from the regulatory authorities would be needed if the trial were to be conducted in the EU in line with EC Directive 2001/20.
- iii. A prospective observational study where the patient is prescribed and treated with an approved medicinal product in accordance with the marketing authorisation and current practice and with the other requirements set out in section 15.01 of the EFPIA HCP Code.
- iv. Other type of activity:

- d. Activities associated with planning the inclusion, design or timing of non-clinical studies, clinical trials and/or prospective observational studies within the context of a development plan for a medicine
- e. Activities associated with planning of particular non-clinical studies, clinical trials or prospective observational studies.
- f. Activities associated with conduct of particular non-clinical studies, clinical trials or prospective observational studies.

Examples of activities that could be covered under “R&D transfer of values” in the Takeda disclosure report: *Clinical trials: regional and/or global, local non-interventional studies*

The transfer of values realized indirectly via a Clinical Research Organisations (CRO), are also included in the R&D section of the disclosure report.

Transfer of values related to R&D are reported as an aggregate total figure, with the exception of transfer of values related to retrospective non-interventional studies, which shall comply with the provisions of Article 15 of the EFPIA HCP Code, which are disclosed under the name of the individual recipient.

## **2.4 Transfer of value in Cross border interactions**

Cross border transfer of values is part of our disclosure report. The cross border activities are disclosed in the country of HCP recipient’s primary practice address.

For instance, if Spanish HCP consultant is contracted by a foreign Takeda legal entity, Takeda will be disclosing the associated transfer(s) of value in the Spanish disclosure report, in line with the HCP primary practice address.

## **2.5 Transfer of value for Patient Organizations.**

Takeda will make public all collaborations with Patient Organizations during the period from January 1, 2020 to December 31, 2020 to which it has provided financial and / or other significant support.

## **3 Privacy consent to the disclosure and aggregate amount**

The disclosure of the individual transfer of value of a HCP is made in accordance with local regulations on data protection. Thus, the legal basis and justification for the transfer of value publication without the consent of the Healthcare Professional (HCP) being necessary, is the existence of legitimate interest, according to the report of the Spanish Agency for Data Protection of April 22, 2016, without any change having occurred regarding to the entry into force of the RGPD that continues to contemplate this legal basis in Article 6.1.f) (former Article 7.f) of Directive 95/46 / EC).

Takeda has informed the Healthcare Professionals, before performing any activity or practice that implies a Transfer of Values, that their data and the referred Transfer of Values will be published on the laboratory’s website, individually, within the six first months of the following year of its realization.

Likewise, Takeda considers that, as interested, the people of the EU have certain rights that may be subject to limitations and / or restrictions. Among these rights are the right to: (i) request access to your Personal Data and the rectification or elimination thereof; (ii) obtain the restriction of the treatment or oppose the processing of your Personal Data; and (iii) the right to data portability.

## 4. Working assumptions

### 4.1 Date of Transfer of Value

Within Takeda, each activity with HCO and HCP is subject to a rigorous need assessment and internal approval process. Upon approval, Takeda moves to contracting which covers Transfer of Value and Disclosure request for consent, whenever relevant. Performance of service requested is tracked, so that payments can be made according to contract terms and conditions.

In our country, and in line with our local industry, we are using the Event date as recognition of transfer of value.

By event date we understand the date on which the activity is carried out, and the date that has been used for the disclosure in this report.

This year and exceptionally, all those transfers of value belonging to L. Shire, made during 2019, and in which the transfer of value was a direct payment made in 2020 will be disclosed in this report. In these cases, records its amount on the date of this, that is, on the date on which the funds are transferred to the beneficiary's bank account. For example, fees and sponsorships whose payment date was made in 2020

The cut-off rule we applied, is the following:

If the event date has taken place between January 1<sup>st</sup> and December 31<sup>st</sup> 2020, the Transfer of Value is in scope for our 2021 disclosure report.

*Takeda has a very limited use of multi-years contracts, mainly related to R&D activities. For the remaining multi-year contracts related to other activities, we have taken into consideration the <services delivered during a calendar year/payments made during a given calendar year> as inclusion criteria for that calendar year related disclosure report.*

### 4.2 Currency

Takeda Farmacéutica España S.A. has adopted the Euro for the disclosure report, as it is - in the moment of the disclosure- the country official currency. In the case a Transfer of Value was made in another currency than the official one, the amount has been converted using Takeda Company Treasury exchange rates, that are monthly updated.

Example of Transfer of Value made in foreign currency, is when the HCP incurred travel costs in a foreign country where he/she is delivering the service which we reimbursed.

### 3.3 Taxes

Fees being paid are subject to taxes. The amounts captured in our report are gross amounts.

#### 4.3.1. Value-Added Tax (VAT)

Expenses such as travel or accommodation are subject to VAT. The data captured and disclosed are excluding VAT.

## 5. Dispute resolution management

Takeda has implemented an internal process for Dispute Resolution Management in case for instance of general questions and disagreements with the data that has reported and/or requests to add or remove HCP/HCO privacy consent to disclose data.

To improve the quality of the data subject to transparency, and prior to its disclosure of the transparency report, Takeda will provide an individual report to healthcare professionals whose value transfers received exceed € 1,500.

If you have comments or questions about Takeda processing of your information, this Methodological Note, the content of the disclosure, or Takeda Privacy Policy, please contact the Compliance department of Takeda Farmacéutica España, at email address "ES\_transparencia@takeda.com" or the contact indicated in the Takeda web site (<http://www.takeda.es>).